A Phase 4 interventional study of Travoprost 0.004% + Brinzolamide 1.0% and Travoprost 0.004% + Tears Natural in Intraocular Pressure, sponsored by Alcon Research. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-05.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
Drug: Travoprost 0.004% + Brinzolamide 1.0%
Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
Drug: Travoprost 0.004% + Tears Natural
Drug page: Travoprost
Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
Drug page: Travoprost
Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
Mean IOP (Intraocular Pressure)
Time frame: Screening: Week 12; (At 9 am and 4 pm time points)
| Milestone | Travoprost 0.004% + Brinzolamide 1.0% | Travoprost 0.004% + Tears Natural |
|---|---|---|
| Started | 19 | 18 |
| Completed | 15 | 17 |
| Not completed | 4 | 1 |
| mm Hg (millimeters mercury) | Travoprost 0.004% + Brinzolamide 1.0% | Travoprost 0.004% + Tears Natural |
|---|---|---|
| 9 AM measurement | 17.58 ± 4.29 | 20.59 ± 3.70 |
| 4 PM measurement | 17.11 ± 4.50 | 18.50 ± 3.05 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Travoprost 0.004% + Brinzolamide 1.0% | — | 0/19 (0%) | 0/19 (0%) |
| Travoprost 0.004% + Tears Natural | — | 0/18 (0%) | 0/18 (0%) |
| Age, Categorical(Participants) | Travoprost 0.004% + Brinzolamide 1.0% | Travoprost 0.004% + Tears Natural | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 15 | 26 |
| >=65 years | 8 | 3 | 11 |
| Sex: Female, Male(Participants) | Travoprost 0.004% + Brinzolamide 1.0% | Travoprost 0.004% + Tears Natural | Total |
|---|---|---|---|
| Female | 14 | 11 | 25 |
| Male | 5 | 7 | 12 |
No study locations are listed for this record.
The record gives a start of May 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost